| Today's Big NewsOct 12, 2022 |
Roche touts Evrysdi win in previously treated SMA patients, turning up heat in rivalry with Biogen and Novartis Merck & Co., in busy morning, taps Moderna's therapeutic cancer vaccine, Royalty in schizophrenia deal Philips warns of lower-than-expected sales, takes another €1.3B hit in Respironics division Bright Health to exit ACA exchanges, slash MA footprint to 2 states BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica AI spots signs of mental health issues in text messages on par with human psychiatrists: UW study Tavros signs $930M biobucks deal with Bayer's Vividion in hunt for 4 oncology targets Walgreens snaps up remaining stake in CareCentrix for $392M Over a 3rd of US counties are 'maternity care deserts,' March of Dimes study finds XACT scores FDA clearance to remote-control its needle surgery robot Ionis, a frequent Big Pharma partner, plots new manufacturing site to support pipeline Moderna says yes to Autolus, licensing targeting technology for immuno-oncology project |
| By Fraiser Kansteiner Armed with new data from what Genentech is touting as one of the biggest and most diverse studies of previously treated spinal muscular atrophy (SMA) patients, the Roche unit is padding its case for Evrysdi in people who may have already received a pricey therapy for their disease. |
|
|
|
By James Waldron Merck & Co. had a busy morning signing off on licensing deals for midstage assets. The Big Pharma not only confirmed it would push ahead with developing a therapeutic cancer vaccine with mRNA leader Moderna but also signed up to collaborate on its schizophrenia treatment with Royalty Pharma. |
By Andrea Park Ahead of its third-quarter earnings report, Philips steeled investors for less-than-stellar sales and order intake growth, compounded by a pair of non-cash charges for the quarter that together amount to nearly 1.5 billion euros. |
By Paige Minemyer The insurtech has announced that it is axing its full lineup of plans on the Affordable Care Act's exchanges and cutting its Medicare Advantage offerings to two states for the 2023 plan year. |
By Angus Liu As BeiGene gears up for an all-out war against AbbVie and Johnson & Johnson’s Imbruvica, the company has turned in more clinical evidence to show it has the winning BTK inhibitor to fight certain blood cancers. |
By Andrea Park The natural language processing model was found to be just as capable as human psychiatrists in spotting certain “cognitive distortions” that may indicate a decline in mental health, suggesting that the AI could serve as a useful tool in triaging patients in an increasingly overtaxed healthcare system. |
By Gabrielle Masson Bayer subsidiary Vividion Therapeutics has partnered with Tavros Therapeutics to find targets for hard-to-treat diseases, paying out $17.5 million cash and offering the biotech up to $912.5 million in biobucks. |
By Heather Landi Walgreens Boots Alliance plans to take full ownership of CareCentrix to push forward its healthcare strategy with a particular focus on primary care, post-acute care and home care. |
By Dave Muoio More than 2.2 million women of childbearing age live in counties without hospitals, birth centers or other providers offering obstetric care, according to a report published Tuesday. |
By Conor Hale Former Fierce 15 winner XACT Robotics collected its second FDA clearance of the year for its palm-sized interventional device. |
By Zoey Becker Ionis Pharmaceuticals unveiled plans for a 217,000-square-foot development chemistry and manufacturing site in Oceanside, California. The company said it expects to occupy the new site by 2025. |
By Nick Paul Taylor After kicking the tires on Autolus Therapeutics’ targeting technology, Moderna has decided to pay up for the right to use the binders in an mRNA therapy. The exercising of the option positions Moderna to use the binders in a candidate against an undisclosed immuno-oncology target. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about the trend of retail giants getting involved primary care. Also under discussion is our special report spotlighting the important contributions made by people of color across health systems, physicians' offices, health tech and insurance companies. |
|
|---|
|
|
|
Monday, October 17, 2022 | 11am ET / 8am PT Given the wide array of post transcriptional and post translational regulatory processes that govern cellular dynamics, additional omics types are needed to capture a more comprehensive understanding of the molecular landscape of a tumor.Register now to learn more. 
|
|
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
